Background: The authors of the current review aspire to inspire researchers by using SAR technique discover a promising and novel therapeutic agent. Currently, we don’t have drug that is both active non-toxic for treatment severe diseases like cancer, diabetes, hypertension, neurodegenerative diseases. In summary, thiazolidinedione (TZD) heterocyclic ligands spectacular standing in medicinal ch...

A series of novel 2, 4-thiazolidinedione derivatives 2-{4-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl] phenoxy}N-(substituted phenyl) acetamides d (1-12) have been accomplished in good yields by stirring 2,4-thiazolidinedione a and 2-(4-formyl phenoxy) N-substituted acetamide c (1-12) at room temperature. Some of the reaction sequences were carried under microwave irradiation which resulte...

Severity of thiazolidinedione (Rosiglitazone)-induced fluid retention is linked almost exclusively to cardiac decompensation. We here report a 68-year old female with type 2 diabetes mellitus, in whom a life-threatening (anasarca type) acute pulmonary edema, induced by rosiglitazone plus insulin therapy, occurred without any evidence of left ventricular systolic or diastolic dysfunction. It see...

AIM/INTRODUCTION To assess the overall safety and efficacy of lixisenatide in combination with background oral antidiabetic drug treatment in Japanese patients with type 2 diabetes, as required by Japanese guidelines. MATERIALS AND METHODS A phase 3, multicenter, uncontrolled, open-label, four-arm, parallel-group study of Japanese outpatients with type 2 diabetes was carried out; patients rec...

BACKGROUND Findings of prior studies have been inconclusive about the ocular effects of thiazolidinediones on diabetic macular edema (DME). We evaluated, in patients with type 2 diabetes (T2D), the short-term and long-term risks of developing DME among users vs nonusers of thiazolidinediones. METHODS A retrospective cohort study of 103,368 patients with T2D and no DME at baseline using The He...

OBJECTIVE To assess glycemic control and secondary failure in patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen in a managed care setting. STUDY DESIGN Retrospective cohort study using administrative claims data. METHODS Participants (mean age, 51.1 years; 55.4% female) were required to have at least 1 prescription claim for a sulfonylurea (n = 300) or a thiaz...